RxDoctor Payments Data

Monica Saumoy, MD

Gastroenterology · Philadelphia, PANPI 1457640484

Payments from drug & device makers

$4,386in general payments, 2019–2025

Across 147 payments — averaging $29.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boston Scientific$962
  • Intuitive Surgical$450
  • BD$319
  • Phathom Pharmaceuticals, Inc.$279
  • Conmed Corporation$151
  • plus $1K from 23 others

What the payments were for

  • Consulting fees$3197%
  • Speaking & faculty fees$45010%
  • Food & beverage$3,60082%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,386 in reported general payments places this provider in the 60th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$188,413
Medicare patients
509
Services billed
1,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase11$94,230
LinzessLinaclotide21$32,320
XifaxanRifaximin15$29,966
Lubiprostone16$5,035
ClenpiqSod Picosulf/Mag Ox/Citric Ac26$4,474
Sucralfate22$4,373
Omeprazole189$2,686
CholestyramineCholestyramine (With Sugar)22$1,633
Esomeprazole Magnesium38$1,239
Famotidine45$848
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates12$836
Rabeprazole Sodium16$825
Pantoprazole Sodium65$719
Lactulose34$415
ConstuloseLactulose17$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,152$126,55032 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$83$29,96615 claims
Ferring Pharmaceuticals Inc.Clenpiq$59$4,47426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →